Evaluation of Tolerability and Efficacy of a Topical Emulgel Containing Nanoliposomal Ruxolitinib Phosphate in the Treatment of Mild Atopic Dermatitis: A Before-After Single Group Pilot Study Publisher Pubmed



Naeimifar A¹ ; Ahmad Nasrollahi S² ; Samadi A² ; Aryanian Z³ ; Akbari Javar H¹ ; Rouini M¹ ; Nassiri Kashani M² ; Firooz A² Show Affiliations
Source: Journal of Dermatological Treatment Published:2022

Abstract

Background: Ruxolitinib is a JAK1/2 inhibitor, which inhibits the signal transduction of interferon-gamma, a cytokine implicated in the pathogenesis of atopic dermatitis (AD). In this before-after single group phase IIA pilot study, we investigated the efficacy of topical nanoliposomal ruxolitinib phosphate (RuxoLip) emulgel in mild AD. Methods: Clinical evaluation was conducted on 10 patients with mild AD. The efficacy of the product as well as patient satisfaction was evaluated by local scoring atopic dermatitis (SCORAD) of AD. In addition, trans-epidermal water loss (TEWL), stratum corneum (SC) hydration, sebum, erythema, melanin content, and ultrasonographic parameters were measured before, and two and four weeks after treatment. Results: Four weeks of treatment reduced SCORAD, itching, and burning (p =.001,.001, and.001, respectively) and increased hydration, sebum, and epidermal density (p =.001,.018, and.037, respectively). SCORAD and other skin biophysical parameters improved within two weeks of treatment and then were in plateau for up to four weeks. Conclusions: The topical ruxolitinib emulgel has good short-term efficacy and tolerability. © 2022 Taylor & Francis Group, LLC.